These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 14966779)

  • 1. Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure.
    Xu J; Carretero OA; Liu YH; Yang F; Shesely EG; Oja-Tebbe N; Yang XP
    J Card Fail; 2004 Feb; 10(1):83-9. PubMed ID: 14966779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat.
    Hegde LG; Yu C; Renner T; Thibodeaux H; Armstrong SR; Park T; Cheruvu M; Olsufka R; Sandvik ER; Lane CE; Budman J; Hill CM; Klein U; Hegde SS
    J Cardiovasc Pharmacol; 2011 Apr; 57(4):495-504. PubMed ID: 21297495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats.
    Kostova E; Jovanoska E; Zafirov D; Jakovski K; Maleska V; Slaninka-Miceska M
    Bratisl Lek Listy; 2005; 106(12):407-11. PubMed ID: 16642666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice.
    Yang XP; Liu YH; Mehta D; Cavasin MA; Shesely E; Xu J; Liu F; Carretero OA
    Circ Res; 2001 May; 88(10):1072-9. PubMed ID: 11375278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice.
    Arnal JF; Castano C; Maupas E; Mugniot A; Darblade B; Gourdy P; Michel JB; Bayard F
    Atherosclerosis; 2001 Apr; 155(2):291-5. PubMed ID: 11254898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.
    Blais C; Fortin D; Rouleau JL; Molinaro G; Adam A
    J Pharmacol Exp Ther; 2000 Nov; 295(2):621-6. PubMed ID: 11046097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin I-converting enzyme-dependent and neutral endopeptidase-dependent generation and degradation of angiotensin II contrarily modulate noradrenaline release: implications for vasopeptidase-inhibitor therapy?
    Raasch W; Dominiak P; Dendorfer A
    J Hypertens; 2005 Aug; 23(8):1597-604. PubMed ID: 16003188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study.
    Solomon SD; Skali H; Bourgoun M; Fang J; Ghali JK; Martelet M; Wojciechowski D; Ansmite B; Skards J; Laks T; Henry D; Packer M; Pfeffer MA;
    Am Heart J; 2005 Aug; 150(2):257-62. PubMed ID: 16086927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure.
    Birner C; Ulucan C; Bratfisch M; Götz T; Dietl A; Schweda F; Riegger GA; Luchner A
    Naunyn Schmiedebergs Arch Pharmacol; 2012 Nov; 385(11):1117-25. PubMed ID: 22895639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure.
    Cataliotti A; Boerrigter G; Chen HH; Jougasaki M; Costello LC; Tsuruda T; Lee SC; Malatino LS; Burnett JC
    Circulation; 2002 Feb; 105(5):639-44. PubMed ID: 11827932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.
    Liu YH; Yang XP; Sharov VG; Nass O; Sabbah HN; Peterson E; Carretero OA
    J Clin Invest; 1997 Apr; 99(8):1926-35. PubMed ID: 9109437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ACE inhibitor, AT1 antagonist, and combined treatment in mice with heart failure.
    Cavasin MA; Yang XP; Liu YH; Mehta D; Karumanchi R; Bulagannawar M; Carretero OA
    J Cardiovasc Pharmacol; 2000 Oct; 36(4):472-80. PubMed ID: 11026648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal damage after myocardial infarction is prevented by renin-angiotensin-aldosterone-system intervention.
    Windt WA; Eijkelkamp WB; Henning RH; Kluppel AC; de Graeff PA; Hillege HL; Schäfer S; de Zeeuw D; van Dokkum RP
    J Am Soc Nephrol; 2006 Nov; 17(11):3059-66. PubMed ID: 17005935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cardioprotective effect of dual metallopeptidase inhibition: respective roles of endogenous kinins and natriuretic peptides.
    Dumoulin MJ; Adam A; Burnett J; Heublein D; Yamaguchi N; Lamontagne D
    Can J Physiol Pharmacol; 2005 Feb; 83(2):166-73. PubMed ID: 15791290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct inhibition of neutral endopeptidase in vasopeptidase inhibitor-mediated amelioration of cardiac remodeling in rats with chronic heart failure.
    Maki T; Nasa Y; Tanonaka K; Takahashi M; Takeo S
    Mol Cell Biochem; 2003 Dec; 254(1-2):265-73. PubMed ID: 14674706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats.
    Grönholm T; Cheng ZJ; Palojoki E; Eriksson A; Bäcklund T; Vuolteenaho O; Finckenberg P; Laine M; Mervaala E; Tikkanen I
    Eur J Pharmacol; 2005 Sep; 519(3):267-76. PubMed ID: 16137672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential tissue and enzyme inhibitory effects of the vasopeptidase inhibitor omapatrilat in the rat.
    Kubota E; Dean RG; Hubner RA; Casley DJ; Johnston CI; Burrell LM
    Clin Sci (Lond); 2003 Sep; 105(3):339-45. PubMed ID: 12741953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ACE/NEP inhibition on cardiac and vascular collagen in stroke-prone spontaneously hypertensive rats.
    Pu Q; Schiffrin EL
    Am J Hypertens; 2001 Oct; 14(10):1067-72. PubMed ID: 11710787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasopeptidase inhibitors: potential role in the treatment of heart failure.
    Trindade PT; Rouleau JL
    Heart Fail Monit; 2001; 2(1):2-7. PubMed ID: 12634892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.